ND-630
| CAS No. | 1434635-54-7 | Cat. No. | BCP20893 |
| Name | ND-630 | ||
| Synonyms | ND 630;ND630;NDI-010976; NDI 010976; NDI010976; GS-0976; GS0976; GS 0976;Firsocostat; | ||
| Formula | C28H31N3O8S | M. Wt | 569.63 |
| Description | ND-630, also known as GS-0976 and NDI-010976, is a potent ACC inhibitor. ND-630 nteracts within the ACC phosphopeptide acceptor and dimerization site to prevent dimerization and inhibit the enzymatic activity of both ACC isozymes, reduce fatty acid synthesis and stimulate fatty acid oxidation in cultured cells and in animals, and exhibit favorable drug-like properties. ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. When administered chronically to Zucker diabetic fatty rats, ND-630 reduces hepatic steatosis, improves glucose-stimulated insulin secretion, and reduces hemoglobin A1c (0.9% reduction). | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | ACC | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.